Description
Title: Clinical Applications Based on Current Evidence: Edoxaban Update for Thromboembolism Prevention and Treatment
Abstract: Heparins and vitamin K antagonists (VKA) have been used to treat and prevent thromboembolism (both arterial and venous) for many years. New findings in the pharmacotherapy of thromboembolism management have been made as a result of targeting and inhibiting particular coagulation factors. Direct oral anticoagulants are the name for these targeted anticoagulants (DOACs). Dabigatran etexilate, a direct oral factor Xa inhibitor (OFXaI), and rivaroxaban, apixaban, and edoxaban are two pharmacologically distinct classes of targeted drugs. DOACs are noninferior to VKA or low-molecular-weight heparins in the prevention and treatment of thromboembolism, according to emerging evidence from clinical trials. Based on the available published literature, this review examines the function of edoxaban, a recently approved OFXaI, in the prevention and treatment of thromboembolism. Edoxaban’s use in cancer patients, reversibility in cases of bleeding, relevance of drug-drug interactions, patient satisfaction, financial effects, and patient education will all be covered.
Paper Quality: SCOPUS / Web of Science Level Research Paper
Subject: Medicine
Sub Category: Hematology
Writer Experience: 20+ Years
Plagiarism Report: Turnitin Plagiarism Report will be less than 10%
Restriction: Only one author may purchase a single paper. The paper will then indicate that it is out of stock.
What will I get after the purchase?
A turnitin plagiarism report of less than 10% in a pdf file and a full research paper in a word document.
In case you have any questions related to this research paper, please feel free to call/ WhatsApp on +919726999915
Reviews
There are no reviews yet.